Dr. Anan pointed out that Paxlowid Better results in the elderly 65 years and older.

Dr. Anan Chongkaewwatana, virologist Director of Animal Health and Management Innovation Research Group National Center for Genetic Engineering and Biotechnology (Biotech), National Science and Technology Development Agency (NSTDA) posted a message via Facebook Anan Jongkaewwattana. by identifying research Published in the journal NEJM, Paxlovid is beneficial for the elderly covid patients aged 65 and over, and younger patients (40-64 years). The treatment effect was not different from the non-prescription group.